Claritev (CTEV) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$2.65

Estimate

$1.71

Surprise

-254.8%

Revenue (period 2026-09-30)

$268.3M

Score at report (before → after)

6.0 → 6.3/10

Revenue source: xbrl.

Claritev (CTEV) reported a wider loss than forecast — adjusted EPS of -$2.65 against the $1.71 estimate (a 254.8% shortfall). TrendMatrix's engine moved from Hold (6.0/10) to Sell at 6.3/10 after the report — the engine's score rose despite the miss.

• Claritev Q3 2026 Earnings Call Transcript — benzinga, 2026-11-09
• Claritev Corporation Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-09
• Claritev Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.038B-$1.043B vs $1.014B Est — benzinga, 2026-11-09

TrendMatrix currently rates CTEV Sell at 6.1/10.

0 of the last 4 quarters beat the estimate; this quarter's -254.8% surprise compares with a -347.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$24.93

Price target

$40.02

Stop

$23.18

Upside to target

+60.6%

Reward-to-risk

4.0:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Health Information Services

Market cap

$406.7M

P/E (fwd)

3.1

52-week range

$11.50–$72.67

Off 52-week high

65.7%

RSI (14)

57

Volume vs avg

1.08×

Score today

6.1/10